Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cnm-znag
- Development stage
- Phase 2
- Lead developer
- Clene
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Topical
01
Overview
CNM-ZnAg is a proprietary zinc-silver ionic solution developed by Clene Nanomedicine. It has demonstrated both antiviral and antibacterial (antimicrobial) activity in preclinical and clinical studies. The drug is being investigated primarily for the treatment of infectious diseases, with a focus on COVID-19, where it has reached Phase 2 clinical trials. Its mechanism of action involves leveraging the antimicrobial properties of zinc and silver ions to inhibit viral and bacterial pathogens[1][2][5]. The product is formulated as an aqueous solution intended for oral administration in symptomatic patients[5]. No significant safety concerns have been reported in clinical studies to date[4].
- Other names
- CNM-ZnAG
02
Targets
Microbial nucleic acid
Beyond the preview
Go deeper on cnm-znag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cnm-znag.